Subrenal capsule assay of human tumor chemosensitivity

• Published in: Neoplasma Vol. 38; no. 3; pp. 275 - 284
• Main Authors: KONOVALOVA, N. P, DIATCHKOVSKAYA, R. F, GANIEVA, L. K, VOLKOVA, L. M, LAPSHIN, I. M, RUDAKOV, B. Y, SHAPOSHNIKOV, Y. G, SHAPIRO, A. B
• Format: Journal Article
• Language: English
• Published: Bratislava Slovak Academic Press 1991
• Subjects: Aclarubicin - analogs & derivatives; Aclarubicin - pharmacology; Animals; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Colonic Neoplasms - drug therapy; Cyclophosphamide - pharmacology; Daunorubicin - analogs & derivatives; Daunorubicin - pharmacology; Daunorubicin - therapeutic use; Dose-Response Relationship, Drug; Doxorubicin - analogs & derivatives; Doxorubicin - therapeutic use; Evaluation Studies as Topic; Fluorouracil - therapeutic use; Humans; Medical sciences; Mice; Neoplasm Transplantation; Pharmacology. Drug treatments; Subrenal Capsule Assay; Antineoplastic agent; Human; Evaluation; Animal model; Renal capsule; Exploration; Malignant tumor; Heterograft; Pathology; Autoradiography; Chemotherapy; Sensitivity resistance; Treatment; Structure activity relation
• ISSN: 0028-2685

Breast and colon tumor response to emoxyl, a nitroxyl derivative of daunomycin, was detected using human tumor heterotransplantation under the renal capsule of immunocompetent mice. The substitution of adriamycin by emoxyl in the combined therapy led to enhanced therapeutic efficacy. The evidence of enhanced response of breast tumors to emoxyl obtained during the histologic examination of xenografts is in good agreement with measurements of tumor fragment weight. It is suggested to use a quantitative kinetic index kappa calculated by the method of equivalent exponents for objective evaluation of tumor response to the drugs.